31 A Modified-Release Drug Delivery Technology Containing Amphetamine-Ion Exchange Complexes Article Swipe
Barry K. Herman
,
Thomas King
,
Judith C. Kando
,
Antonio Pardo
·
YOU?
·
· 2019
· Open Access
·
· DOI: https://doi.org/10.1017/s1092852919000257
YOU?
·
· 2019
· Open Access
·
· DOI: https://doi.org/10.1017/s1092852919000257
The proprietary, immediate and extended drug delivery technologyLiquiXR® utilizes an ion-exchange resin that complexes with amphetamine or any active moiety that can be protonated and is water-soluble. The active ingredient of the drug product forms a complex with an ion exchange polymer of the resin resulting in micron-sized particles. A portion of these particles is then coated with an aqueous, pH-independent polymer designed to provide sustained release of drug product. The polymer coating applied to the ion-exchange resin particles is of varying thickness, allowing for extended release of active drug while uncoated particles provide for immediate release of drug. The micron-sized particles lend themselves to being formulated into an appropriate dosage form: solid/chewable tablet, liquid suspension, orally disintegrating tablet, film, or capsules. Active ingredient of drug product is subsequently released from the dosage form in millions of particles, with release driven by a combination of ion exchange and diffusion. After drug release, the ion-exchange resin particles are excreted in the feces. The release characteristics of LiquiXR allow for customized, sustained release of active drug ∼24hours post dose. Mechanistically, drug particles enter the gastrointestinal (GI) tract. As positively-charged ions from GI fluids diffuse across the coating, it displaces drug ions from product and they diffuse through the coating and into the GI fluids for absorption. As the coating is of variable thickness, some drug product takes longer to diffuse and absorb, providing for the delayed drug release characteristics. The LiquiXR drug delivery technology has already been successfully utilized in the development of treatment options (liquid suspension and chewable tablet) that offer rapid absorption and sustained plasma levels after once-daily dosing. LiquiXR is utilized in Dyanavel® XR (amphetamine extended-release oral suspension; AMPH EROS), which is indicated for treatment of ADHD. It comprises 2.5mg/mL amphetamine base and uses LiquiXR technology to provide an immediate release component followed by an extended-release profile. Efficacy of AMPH EROS was established in children 6 to 12 yr in a Phase 3, placebo-controlled laboratory classroom study. In that study, ADHD symptoms in children on an individually optimized dose of amphetamine (range 10–20mg/day) were statistically significantly improved compared with symptoms in children treated with placebo. For children treated with AMPH EROS, onset of effect was demonstrated at 1hour after dosing, and efficacy was observed through 13hr post-dose. The effect size (ES) was comparable to ES demonstrated for other psychostimulants tested in studies using a similar design. The efficacy data reported for AMPH EROS provides an excellent example of the potential utility and clinical application for other active drug products requiring an immediate and extended release profile. Funding Acknowledgements: Support provided by Tris Pharma, Inc.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1017/s1092852919000257
- https://www.cambridge.org/core/services/aop-cambridge-core/content/view/D72A6EFF5F7CD929877AFD6DE8095B0A/S1092852919000257a.pdf/div-class-title-31-a-modified-release-drug-delivery-technology-containing-amphetamine-ion-exchange-complexes-div.pdf
- OA Status
- bronze
- Cited By
- 2
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2921821858
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2921821858Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1017/s1092852919000257Digital Object Identifier
- Title
-
31 A Modified-Release Drug Delivery Technology Containing Amphetamine-Ion Exchange ComplexesWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2019Year of publication
- Publication date
-
2019-02-01Full publication date if available
- Authors
-
Barry K. Herman, Thomas King, Judith C. Kando, Antonio PardoList of authors in order
- Landing page
-
https://doi.org/10.1017/s1092852919000257Publisher landing page
- PDF URL
-
https://www.cambridge.org/core/services/aop-cambridge-core/content/view/D72A6EFF5F7CD929877AFD6DE8095B0A/S1092852919000257a.pdf/div-class-title-31-a-modified-release-drug-delivery-technology-containing-amphetamine-ion-exchange-complexes-div.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://www.cambridge.org/core/services/aop-cambridge-core/content/view/D72A6EFF5F7CD929877AFD6DE8095B0A/S1092852919000257a.pdf/div-class-title-31-a-modified-release-drug-delivery-technology-containing-amphetamine-ion-exchange-complexes-div.pdfDirect OA link when available
- Concepts
-
Active ingredient, Drug, Coating, Chemistry, Drug delivery, Ion-exchange resin, Dosage form, Polymer, Nanoparticle, Ion exchange, Nanotechnology, Materials science, Chromatography, Ion, Organic chemistry, Pharmacology, MedicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
2Total citation count in OpenAlex
- Citations by year (recent)
-
2019: 2Per-year citation counts (last 5 years)
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2921821858 |
|---|---|
| doi | https://doi.org/10.1017/s1092852919000257 |
| ids.doi | https://doi.org/10.1017/s1092852919000257 |
| ids.mag | 2921821858 |
| ids.openalex | https://openalex.org/W2921821858 |
| fwci | 0.22183063 |
| type | article |
| title | 31 A Modified-Release Drug Delivery Technology Containing Amphetamine-Ion Exchange Complexes |
| biblio.issue | 1 |
| biblio.volume | 24 |
| biblio.last_page | 191 |
| biblio.first_page | 191 |
| topics[0].id | https://openalex.org/T10256 |
| topics[0].field.id | https://openalex.org/fields/30 |
| topics[0].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[0].score | 0.9944999814033508 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/3003 |
| topics[0].subfield.display_name | Pharmaceutical Science |
| topics[0].display_name | Drug Solubulity and Delivery Systems |
| topics[1].id | https://openalex.org/T10920 |
| topics[1].field.id | https://openalex.org/fields/30 |
| topics[1].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[1].score | 0.992900013923645 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/3003 |
| topics[1].subfield.display_name | Pharmaceutical Science |
| topics[1].display_name | Advanced Drug Delivery Systems |
| topics[2].id | https://openalex.org/T11460 |
| topics[2].field.id | https://openalex.org/fields/16 |
| topics[2].field.display_name | Chemistry |
| topics[2].score | 0.9811000227928162 |
| topics[2].domain.id | https://openalex.org/domains/3 |
| topics[2].domain.display_name | Physical Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1602 |
| topics[2].subfield.display_name | Analytical Chemistry |
| topics[2].display_name | Analytical Methods in Pharmaceuticals |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C45904493 |
| concepts[0].level | 2 |
| concepts[0].score | 0.71595299243927 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q912807 |
| concepts[0].display_name | Active ingredient |
| concepts[1].id | https://openalex.org/C2780035454 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6487278342247009 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[1].display_name | Drug |
| concepts[2].id | https://openalex.org/C2781448156 |
| concepts[2].level | 2 |
| concepts[2].score | 0.581438422203064 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1570182 |
| concepts[2].display_name | Coating |
| concepts[3].id | https://openalex.org/C185592680 |
| concepts[3].level | 0 |
| concepts[3].score | 0.5604004263877869 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[3].display_name | Chemistry |
| concepts[4].id | https://openalex.org/C2779820397 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5169053077697754 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1392806 |
| concepts[4].display_name | Drug delivery |
| concepts[5].id | https://openalex.org/C73523448 |
| concepts[5].level | 2 |
| concepts[5].score | 0.4807015061378479 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q1989369 |
| concepts[5].display_name | Ion-exchange resin |
| concepts[6].id | https://openalex.org/C77281830 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4654918909072876 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q718608 |
| concepts[6].display_name | Dosage form |
| concepts[7].id | https://openalex.org/C521977710 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4527072310447693 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q81163 |
| concepts[7].display_name | Polymer |
| concepts[8].id | https://openalex.org/C155672457 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4317992031574249 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q61231 |
| concepts[8].display_name | Nanoparticle |
| concepts[9].id | https://openalex.org/C117760992 |
| concepts[9].level | 3 |
| concepts[9].score | 0.4151102304458618 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q389137 |
| concepts[9].display_name | Ion exchange |
| concepts[10].id | https://openalex.org/C171250308 |
| concepts[10].level | 1 |
| concepts[10].score | 0.33206820487976074 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11468 |
| concepts[10].display_name | Nanotechnology |
| concepts[11].id | https://openalex.org/C192562407 |
| concepts[11].level | 0 |
| concepts[11].score | 0.3097366988658905 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q228736 |
| concepts[11].display_name | Materials science |
| concepts[12].id | https://openalex.org/C43617362 |
| concepts[12].level | 1 |
| concepts[12].score | 0.3053537607192993 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q170050 |
| concepts[12].display_name | Chromatography |
| concepts[13].id | https://openalex.org/C145148216 |
| concepts[13].level | 2 |
| concepts[13].score | 0.29943177103996277 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q36496 |
| concepts[13].display_name | Ion |
| concepts[14].id | https://openalex.org/C178790620 |
| concepts[14].level | 1 |
| concepts[14].score | 0.21486413478851318 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q11351 |
| concepts[14].display_name | Organic chemistry |
| concepts[15].id | https://openalex.org/C98274493 |
| concepts[15].level | 1 |
| concepts[15].score | 0.16223299503326416 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[15].display_name | Pharmacology |
| concepts[16].id | https://openalex.org/C71924100 |
| concepts[16].level | 0 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[16].display_name | Medicine |
| keywords[0].id | https://openalex.org/keywords/active-ingredient |
| keywords[0].score | 0.71595299243927 |
| keywords[0].display_name | Active ingredient |
| keywords[1].id | https://openalex.org/keywords/drug |
| keywords[1].score | 0.6487278342247009 |
| keywords[1].display_name | Drug |
| keywords[2].id | https://openalex.org/keywords/coating |
| keywords[2].score | 0.581438422203064 |
| keywords[2].display_name | Coating |
| keywords[3].id | https://openalex.org/keywords/chemistry |
| keywords[3].score | 0.5604004263877869 |
| keywords[3].display_name | Chemistry |
| keywords[4].id | https://openalex.org/keywords/drug-delivery |
| keywords[4].score | 0.5169053077697754 |
| keywords[4].display_name | Drug delivery |
| keywords[5].id | https://openalex.org/keywords/ion-exchange-resin |
| keywords[5].score | 0.4807015061378479 |
| keywords[5].display_name | Ion-exchange resin |
| keywords[6].id | https://openalex.org/keywords/dosage-form |
| keywords[6].score | 0.4654918909072876 |
| keywords[6].display_name | Dosage form |
| keywords[7].id | https://openalex.org/keywords/polymer |
| keywords[7].score | 0.4527072310447693 |
| keywords[7].display_name | Polymer |
| keywords[8].id | https://openalex.org/keywords/nanoparticle |
| keywords[8].score | 0.4317992031574249 |
| keywords[8].display_name | Nanoparticle |
| keywords[9].id | https://openalex.org/keywords/ion-exchange |
| keywords[9].score | 0.4151102304458618 |
| keywords[9].display_name | Ion exchange |
| keywords[10].id | https://openalex.org/keywords/nanotechnology |
| keywords[10].score | 0.33206820487976074 |
| keywords[10].display_name | Nanotechnology |
| keywords[11].id | https://openalex.org/keywords/materials-science |
| keywords[11].score | 0.3097366988658905 |
| keywords[11].display_name | Materials science |
| keywords[12].id | https://openalex.org/keywords/chromatography |
| keywords[12].score | 0.3053537607192993 |
| keywords[12].display_name | Chromatography |
| keywords[13].id | https://openalex.org/keywords/ion |
| keywords[13].score | 0.29943177103996277 |
| keywords[13].display_name | Ion |
| keywords[14].id | https://openalex.org/keywords/organic-chemistry |
| keywords[14].score | 0.21486413478851318 |
| keywords[14].display_name | Organic chemistry |
| keywords[15].id | https://openalex.org/keywords/pharmacology |
| keywords[15].score | 0.16223299503326416 |
| keywords[15].display_name | Pharmacology |
| language | en |
| locations[0].id | doi:10.1017/s1092852919000257 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210237982 |
| locations[0].source.issn | 1092-8529, 2165-6509 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1092-8529 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | CNS Spectrums |
| locations[0].source.host_organization | https://openalex.org/P4310311721 |
| locations[0].source.host_organization_name | Cambridge University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311721 |
| locations[0].license | |
| locations[0].pdf_url | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/D72A6EFF5F7CD929877AFD6DE8095B0A/S1092852919000257a.pdf/div-class-title-31-a-modified-release-drug-delivery-technology-containing-amphetamine-ion-exchange-complexes-div.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | CNS Spectrums |
| locations[0].landing_page_url | https://doi.org/10.1017/s1092852919000257 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5022439742 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4404-3438 |
| authorships[0].author.display_name | Barry K. Herman |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210162140 |
| authorships[0].affiliations[0].raw_affiliation_string | Tris Pharma, Inc., Monmouth Junction, NJ |
| authorships[0].institutions[0].id | https://openalex.org/I4210162140 |
| authorships[0].institutions[0].ror | https://ror.org/04wqwae75 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210162140 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Tris Pharma (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Barry K. Herman |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Tris Pharma, Inc., Monmouth Junction, NJ |
| authorships[1].author.id | https://openalex.org/A5101669863 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-8487-6592 |
| authorships[1].author.display_name | Thomas King |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210162140 |
| authorships[1].affiliations[0].raw_affiliation_string | Tris Pharma, Inc., Monmouth Junction, NJ |
| authorships[1].institutions[0].id | https://openalex.org/I4210162140 |
| authorships[1].institutions[0].ror | https://ror.org/04wqwae75 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210162140 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Tris Pharma (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Thomas R. King |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Tris Pharma, Inc., Monmouth Junction, NJ |
| authorships[2].author.id | https://openalex.org/A5002980051 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6637-449X |
| authorships[2].author.display_name | Judith C. Kando |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210162140 |
| authorships[2].affiliations[0].raw_affiliation_string | Tris Pharma, Inc., Monmouth Junction, NJ |
| authorships[2].institutions[0].id | https://openalex.org/I4210162140 |
| authorships[2].institutions[0].ror | https://ror.org/04wqwae75 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210162140 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Tris Pharma (United States) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Judith C. Kando |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Tris Pharma, Inc., Monmouth Junction, NJ |
| authorships[3].author.id | https://openalex.org/A5033530186 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-5421-8177 |
| authorships[3].author.display_name | Antonio Pardo |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210162140 |
| authorships[3].affiliations[0].raw_affiliation_string | Tris Pharma, Inc., Monmouth Junction, NJ |
| authorships[3].institutions[0].id | https://openalex.org/I4210162140 |
| authorships[3].institutions[0].ror | https://ror.org/04wqwae75 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210162140 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Tris Pharma (United States) |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Antonio Pardo |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Tris Pharma, Inc., Monmouth Junction, NJ |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/D72A6EFF5F7CD929877AFD6DE8095B0A/S1092852919000257a.pdf/div-class-title-31-a-modified-release-drug-delivery-technology-containing-amphetamine-ion-exchange-complexes-div.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | 31 A Modified-Release Drug Delivery Technology Containing Amphetamine-Ion Exchange Complexes |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10256 |
| primary_topic.field.id | https://openalex.org/fields/30 |
| primary_topic.field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| primary_topic.score | 0.9944999814033508 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/3003 |
| primary_topic.subfield.display_name | Pharmaceutical Science |
| primary_topic.display_name | Drug Solubulity and Delivery Systems |
| related_works | https://openalex.org/W2184114051, https://openalex.org/W2131293645, https://openalex.org/W2133672219, https://openalex.org/W1976666153, https://openalex.org/W2388858187, https://openalex.org/W2140747571, https://openalex.org/W2318856597, https://openalex.org/W2601270567, https://openalex.org/W2371861721, https://openalex.org/W2356495801 |
| cited_by_count | 2 |
| counts_by_year[0].year | 2019 |
| counts_by_year[0].cited_by_count | 2 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1017/s1092852919000257 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210237982 |
| best_oa_location.source.issn | 1092-8529, 2165-6509 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1092-8529 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | CNS Spectrums |
| best_oa_location.source.host_organization | https://openalex.org/P4310311721 |
| best_oa_location.source.host_organization_name | Cambridge University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311721 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/D72A6EFF5F7CD929877AFD6DE8095B0A/S1092852919000257a.pdf/div-class-title-31-a-modified-release-drug-delivery-technology-containing-amphetamine-ion-exchange-complexes-div.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | CNS Spectrums |
| best_oa_location.landing_page_url | https://doi.org/10.1017/s1092852919000257 |
| primary_location.id | doi:10.1017/s1092852919000257 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210237982 |
| primary_location.source.issn | 1092-8529, 2165-6509 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1092-8529 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | CNS Spectrums |
| primary_location.source.host_organization | https://openalex.org/P4310311721 |
| primary_location.source.host_organization_name | Cambridge University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311721 |
| primary_location.license | |
| primary_location.pdf_url | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/D72A6EFF5F7CD929877AFD6DE8095B0A/S1092852919000257a.pdf/div-class-title-31-a-modified-release-drug-delivery-technology-containing-amphetamine-ion-exchange-complexes-div.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | CNS Spectrums |
| primary_location.landing_page_url | https://doi.org/10.1017/s1092852919000257 |
| publication_date | 2019-02-01 |
| publication_year | 2019 |
| referenced_works_count | 0 |
| abstract_inverted_index.6 | 317 |
| abstract_inverted_index.A | 50 |
| abstract_inverted_index.a | 36, 143, 322, 395 |
| abstract_inverted_index.12 | 319 |
| abstract_inverted_index.3, | 324 |
| abstract_inverted_index.As | 186, 215 |
| abstract_inverted_index.ES | 386 |
| abstract_inverted_index.GI | 190, 211 |
| abstract_inverted_index.In | 329 |
| abstract_inverted_index.It | 289 |
| abstract_inverted_index.XR | 275 |
| abstract_inverted_index.an | 10, 39, 59, 109, 300, 306, 337, 406, 422 |
| abstract_inverted_index.at | 368 |
| abstract_inverted_index.be | 23 |
| abstract_inverted_index.by | 142, 305, 432 |
| abstract_inverted_index.in | 47, 135, 159, 248, 273, 315, 321, 334, 352, 392 |
| abstract_inverted_index.is | 26, 55, 80, 128, 218, 271, 283 |
| abstract_inverted_index.it | 196 |
| abstract_inverted_index.of | 31, 43, 52, 68, 81, 88, 98, 125, 137, 145, 165, 172, 219, 251, 287, 310, 341, 364, 409 |
| abstract_inverted_index.on | 336 |
| abstract_inverted_index.or | 17, 121 |
| abstract_inverted_index.to | 64, 75, 105, 227, 298, 318, 385 |
| abstract_inverted_index.yr | 320 |
| abstract_inverted_index.For | 357 |
| abstract_inverted_index.The | 1, 28, 71, 100, 162, 238, 379, 398 |
| abstract_inverted_index.and | 4, 25, 148, 202, 208, 229, 256, 263, 294, 372, 413, 424 |
| abstract_inverted_index.any | 18 |
| abstract_inverted_index.are | 157 |
| abstract_inverted_index.can | 22 |
| abstract_inverted_index.for | 85, 95, 168, 213, 232, 285, 388, 402, 416 |
| abstract_inverted_index.has | 243 |
| abstract_inverted_index.ion | 40, 146 |
| abstract_inverted_index.the | 32, 44, 76, 132, 153, 160, 182, 194, 206, 210, 216, 233, 249, 410 |
| abstract_inverted_index.was | 313, 366, 374, 383 |
| abstract_inverted_index.(ES) | 382 |
| abstract_inverted_index.(GI) | 184 |
| abstract_inverted_index.13hr | 377 |
| abstract_inverted_index.ADHD | 332 |
| abstract_inverted_index.AMPH | 280, 311, 361, 403 |
| abstract_inverted_index.EROS | 312, 404 |
| abstract_inverted_index.Inc. | 435 |
| abstract_inverted_index.Tris | 433 |
| abstract_inverted_index.base | 293 |
| abstract_inverted_index.been | 245 |
| abstract_inverted_index.data | 400 |
| abstract_inverted_index.dose | 340 |
| abstract_inverted_index.drug | 6, 33, 69, 90, 126, 151, 174, 179, 198, 223, 235, 240, 419 |
| abstract_inverted_index.form | 134 |
| abstract_inverted_index.from | 131, 189, 200 |
| abstract_inverted_index.into | 108, 209 |
| abstract_inverted_index.ions | 188, 199 |
| abstract_inverted_index.lend | 103 |
| abstract_inverted_index.oral | 278 |
| abstract_inverted_index.post | 176 |
| abstract_inverted_index.size | 381 |
| abstract_inverted_index.some | 222 |
| abstract_inverted_index.that | 13, 21, 259, 330 |
| abstract_inverted_index.then | 56 |
| abstract_inverted_index.they | 203 |
| abstract_inverted_index.uses | 295 |
| abstract_inverted_index.were | 345 |
| abstract_inverted_index.with | 15, 38, 58, 139, 350, 355, 360 |
| abstract_inverted_index.1hour | 369 |
| abstract_inverted_index.ADHD. | 288 |
| abstract_inverted_index.After | 150 |
| abstract_inverted_index.EROS, | 362 |
| abstract_inverted_index.Phase | 323 |
| abstract_inverted_index.after | 267, 370 |
| abstract_inverted_index.allow | 167 |
| abstract_inverted_index.being | 106 |
| abstract_inverted_index.dose. | 177 |
| abstract_inverted_index.drug. | 99 |
| abstract_inverted_index.enter | 181 |
| abstract_inverted_index.film, | 120 |
| abstract_inverted_index.form: | 112 |
| abstract_inverted_index.forms | 35 |
| abstract_inverted_index.offer | 260 |
| abstract_inverted_index.onset | 363 |
| abstract_inverted_index.other | 389, 417 |
| abstract_inverted_index.rapid | 261 |
| abstract_inverted_index.resin | 12, 45, 78, 155 |
| abstract_inverted_index.takes | 225 |
| abstract_inverted_index.these | 53 |
| abstract_inverted_index.using | 394 |
| abstract_inverted_index.which | 282 |
| abstract_inverted_index.while | 91 |
| abstract_inverted_index.(range | 343 |
| abstract_inverted_index.Active | 123 |
| abstract_inverted_index.EROS), | 281 |
| abstract_inverted_index.across | 193 |
| abstract_inverted_index.active | 19, 29, 89, 173, 418 |
| abstract_inverted_index.coated | 57 |
| abstract_inverted_index.dosage | 111, 133 |
| abstract_inverted_index.driven | 141 |
| abstract_inverted_index.effect | 365, 380 |
| abstract_inverted_index.feces. | 161 |
| abstract_inverted_index.fluids | 191, 212 |
| abstract_inverted_index.levels | 266 |
| abstract_inverted_index.liquid | 115 |
| abstract_inverted_index.longer | 226 |
| abstract_inverted_index.moiety | 20 |
| abstract_inverted_index.orally | 117 |
| abstract_inverted_index.plasma | 265 |
| abstract_inverted_index.study, | 331 |
| abstract_inverted_index.study. | 328 |
| abstract_inverted_index.tested | 391 |
| abstract_inverted_index.tract. | 185 |
| abstract_inverted_index.(liquid | 254 |
| abstract_inverted_index.Funding | 428 |
| abstract_inverted_index.LiquiXR | 166, 239, 270, 296 |
| abstract_inverted_index.Pharma, | 434 |
| abstract_inverted_index.Support | 430 |
| abstract_inverted_index.absorb, | 230 |
| abstract_inverted_index.already | 244 |
| abstract_inverted_index.applied | 74 |
| abstract_inverted_index.coating | 73, 207, 217 |
| abstract_inverted_index.complex | 37 |
| abstract_inverted_index.delayed | 234 |
| abstract_inverted_index.design. | 397 |
| abstract_inverted_index.diffuse | 192, 204, 228 |
| abstract_inverted_index.dosing, | 371 |
| abstract_inverted_index.dosing. | 269 |
| abstract_inverted_index.example | 408 |
| abstract_inverted_index.options | 253 |
| abstract_inverted_index.polymer | 42, 62, 72 |
| abstract_inverted_index.portion | 51 |
| abstract_inverted_index.product | 34, 127, 201, 224 |
| abstract_inverted_index.provide | 65, 94, 299 |
| abstract_inverted_index.release | 67, 87, 97, 140, 163, 171, 236, 302, 426 |
| abstract_inverted_index.similar | 396 |
| abstract_inverted_index.studies | 393 |
| abstract_inverted_index.tablet) | 258 |
| abstract_inverted_index.tablet, | 114, 119 |
| abstract_inverted_index.through | 205, 376 |
| abstract_inverted_index.treated | 354, 359 |
| abstract_inverted_index.utility | 412 |
| abstract_inverted_index.varying | 82 |
| abstract_inverted_index.2.5mg/mL | 291 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Efficacy | 309 |
| abstract_inverted_index.allowing | 84 |
| abstract_inverted_index.aqueous, | 60 |
| abstract_inverted_index.chewable | 257 |
| abstract_inverted_index.children | 316, 335, 353, 358 |
| abstract_inverted_index.clinical | 414 |
| abstract_inverted_index.coating, | 195 |
| abstract_inverted_index.compared | 349 |
| abstract_inverted_index.delivery | 7, 241 |
| abstract_inverted_index.designed | 63 |
| abstract_inverted_index.efficacy | 373, 399 |
| abstract_inverted_index.exchange | 41, 147 |
| abstract_inverted_index.excreted | 158 |
| abstract_inverted_index.extended | 5, 86, 425 |
| abstract_inverted_index.followed | 304 |
| abstract_inverted_index.improved | 348 |
| abstract_inverted_index.millions | 136 |
| abstract_inverted_index.observed | 375 |
| abstract_inverted_index.placebo. | 356 |
| abstract_inverted_index.product. | 70 |
| abstract_inverted_index.products | 420 |
| abstract_inverted_index.profile. | 308, 427 |
| abstract_inverted_index.provided | 431 |
| abstract_inverted_index.provides | 405 |
| abstract_inverted_index.release, | 152 |
| abstract_inverted_index.released | 130 |
| abstract_inverted_index.reported | 401 |
| abstract_inverted_index.symptoms | 333, 351 |
| abstract_inverted_index.uncoated | 92 |
| abstract_inverted_index.utilized | 247, 272 |
| abstract_inverted_index.utilizes | 9 |
| abstract_inverted_index.variable | 220 |
| abstract_inverted_index.capsules. | 122 |
| abstract_inverted_index.classroom | 327 |
| abstract_inverted_index.complexes | 14 |
| abstract_inverted_index.component | 303 |
| abstract_inverted_index.comprises | 290 |
| abstract_inverted_index.displaces | 197 |
| abstract_inverted_index.excellent | 407 |
| abstract_inverted_index.immediate | 3, 96, 301, 423 |
| abstract_inverted_index.indicated | 284 |
| abstract_inverted_index.optimized | 339 |
| abstract_inverted_index.particles | 54, 79, 93, 102, 156, 180 |
| abstract_inverted_index.potential | 411 |
| abstract_inverted_index.providing | 231 |
| abstract_inverted_index.requiring | 421 |
| abstract_inverted_index.resulting | 46 |
| abstract_inverted_index.sustained | 66, 170, 264 |
| abstract_inverted_index.treatment | 252, 286 |
| abstract_inverted_index.Dyanavel® | 274 |
| abstract_inverted_index.absorption | 262 |
| abstract_inverted_index.comparable | 384 |
| abstract_inverted_index.diffusion. | 149 |
| abstract_inverted_index.formulated | 107 |
| abstract_inverted_index.ingredient | 30, 124 |
| abstract_inverted_index.laboratory | 326 |
| abstract_inverted_index.once-daily | 268 |
| abstract_inverted_index.particles, | 138 |
| abstract_inverted_index.particles. | 49 |
| abstract_inverted_index.post-dose. | 378 |
| abstract_inverted_index.protonated | 24 |
| abstract_inverted_index.suspension | 255 |
| abstract_inverted_index.technology | 242, 297 |
| abstract_inverted_index.themselves | 104 |
| abstract_inverted_index.thickness, | 83, 221 |
| abstract_inverted_index.∼24hours | 175 |
| abstract_inverted_index.absorption. | 214 |
| abstract_inverted_index.amphetamine | 16, 292, 342 |
| abstract_inverted_index.application | 415 |
| abstract_inverted_index.appropriate | 110 |
| abstract_inverted_index.combination | 144 |
| abstract_inverted_index.customized, | 169 |
| abstract_inverted_index.development | 250 |
| abstract_inverted_index.established | 314 |
| abstract_inverted_index.suspension, | 116 |
| abstract_inverted_index.suspension; | 279 |
| abstract_inverted_index.(amphetamine | 276 |
| abstract_inverted_index.demonstrated | 367, 387 |
| abstract_inverted_index.individually | 338 |
| abstract_inverted_index.ion-exchange | 11, 77, 154 |
| abstract_inverted_index.micron-sized | 48, 101 |
| abstract_inverted_index.proprietary, | 2 |
| abstract_inverted_index.subsequently | 129 |
| abstract_inverted_index.successfully | 246 |
| abstract_inverted_index.significantly | 347 |
| abstract_inverted_index.statistically | 346 |
| abstract_inverted_index.10–20mg/day) | 344 |
| abstract_inverted_index.disintegrating | 118 |
| abstract_inverted_index.pH-independent | 61 |
| abstract_inverted_index.solid/chewable | 113 |
| abstract_inverted_index.water-soluble. | 27 |
| abstract_inverted_index.characteristics | 164 |
| abstract_inverted_index.Mechanistically, | 178 |
| abstract_inverted_index.characteristics. | 237 |
| abstract_inverted_index.extended-release | 277, 307 |
| abstract_inverted_index.gastrointestinal | 183 |
| abstract_inverted_index.psychostimulants | 390 |
| abstract_inverted_index.Acknowledgements: | 429 |
| abstract_inverted_index.placebo-controlled | 325 |
| abstract_inverted_index.positively-charged | 187 |
| abstract_inverted_index.technologyLiquiXR® | 8 |
| cited_by_percentile_year.max | 96 |
| cited_by_percentile_year.min | 94 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 4 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.41999998688697815 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.42712879 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |